Claims
- 1. A method of modulating expression, production, or formation of amyloid precursor protein (APP) in a subject, comprising administering to said subject an effective amount of an antagonist of a receptor that is coupled to cellular levels of cAMP or to ion channels, wherein said antagonist is a non-steroidal anti-inflammatory agent that is a specific inhibitor of cyclo-oxygenase activity, in a pharmaceutically acceptable carrier.
- 2. A method for enhancing secretion of a soluble form of APP in a subject, said method comprising administering to said subject a specific inhibitor of cyclo-oxygenase activity, in a pharmaceutically acceptable carrier.
- 3. A method for decreasing intracellular amyloidogenic APP holoprotein in a subject, said method comprising administering to said subject a specific inhibitor of cyclo-oxygenase activity, in a pharmaceutically acceptable carrier.
- 4. A method for decreasing overexpression of amyloidogenic APP and amyloidogenic APP peptides in a subject with a neurodegenerative condition, said method comprising administering to said subject a specific inhibitor of cyclo-oxygenase activity, in a pharmaceutically acceptable carrier.
- 5. The method as in claim 4 wherein said neurodegenerative condition is stroke, cerebral ischemia, a de-myelinating condition, or mechanical injury.
- 6. A method for treating immune or inflammatory conditions associated with Alzheimers Disease in a subject, said method comprising administering to said subject a specific inhibitor of cyclo-oxygenase activity, in a pharmaceutically acceptable carrier.
- 7. A method for preventing Alzheimers Disease in a subject, said method comprising administering to said subject an effective amount of a specific inhibitor of cyclo-oxygenase activity, in a pharmaceutically acceptable carrier.
- 8. The method as in claim 1 in which said specific inhibitor of cyclo-oxygenase activity is a specific inhibitor of cyclo-oxygenase type 2 activity.
- 9. The method as in claim 2 in which said specific inhibitor of cyclo-oxygenase activity is a specific inhibitor of cyclo-oxygenase type 2 activity.
- 10. The method as in claim 3 in which said specific inhibitor of cyclo-oxygenase activity is a specific inhibitor of cyclo-oxygenase type 2 activity.
- 11. The method as in claim 4 in which said specific inhibitor of cyclo-oxygenase activity is a specific inhibitor of cyclo-oxygenase type 2 activity.
- 12. The method as in claim 6 in which said specific inhibitor of cyclo-oxygenase activity is a specific inhibitor of cyclo-oxygenase type 2 activity.
- 13. The method as in claim 7 in which said specific inhibitor of cyclo-oxygenase activity is a specific inhibitor of cyclo-oxygenase type 2 activity.
- 14. The method as in claim 8 in which said specific inhibitor of cyclo-oxygenase type 2 activity is DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl) phenyl-2(5H)-furanone), DFP (5,5-dimethyl-3-isopropyloxy-4-(4′-methylsulfonylphenyl)-2(5H)-furanone), resveratrol, or mixtures thereof.
- 15. The method as in claim 9 in which said specific inhibitor of cyclo-oxygenase type 2 activity is DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone), DFP (5,5-dimethyl-3-isopropyloxy-4-(4′-methylsulfonylphenyl)-2(5H)-furanone), resveratrol, or mixtures thereof.
- 16. The method as in claim 10 in which said specific inhibitor of cyclo-oxygenase type 2 activity is DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone), DFP (5,5-dimethyl-3-isopropyloxy-4-(4′-methylsulfonylphenyl)-2(5H)-furanone), resveratrol, or mixtures thereof.
- 17. The method as in claim 11 in which said specific inhibitor of cyclo-oxygenase type 2 activity is DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone), DFP (5,5-dimethyl-3-isopropyloxy-4-(4′-methylsulfonylphenyl)-2(5H)-furanone), resveratrol, or mixtures thereof.
- 18. The method as in claim 12 in which said specific inhibitor of cyclo-oxygenase type 2 activity is DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone), DFP (5,5-dimethyl-3-isopropyloxy-4-(4′-methylsulfonylphenyl)-2(5H)-furanone), resveratrol, or mixtures thereof.
- 19. The method as in claim 13 in which said specific inhibitor of cyclo-oxygenase type 2 activity is DFU (5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone), DFP (5,5-dimethyl-3-isopropyloxy-4-(4′-methylsulfonylphenyl)-2(5H)-furanone), resveratrol, or mixtures thereof.
RELATED APPLICATIONS
[0001] The present application is a continuation-in-part of co-pending U.S. application Ser. No. 08/924,505 filed Sep. 5, 1997, which is related to U.S. Provisional Application No. 60/025,507, filed Sep. 5, 1996, and U.S. Provisional Application No. 60/033,765, filed Jan. 15, 1997.
STATEMENT OF FEDERAL SUPPORT
[0002] The present invention is made in whole or in part with financial support from the Federal Government under grant NIH #MH-28783. The Federal Government may have rights in the invention.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60025507 |
Sep 1996 |
US |
|
60033765 |
Jan 1997 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09435470 |
Nov 1999 |
US |
Child |
09775809 |
Feb 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08924505 |
Sep 1997 |
US |
Child |
09435470 |
Nov 1999 |
US |